Payment overview · 2025
General Payments
$530.44
23 reported records · 14 companies
Healthcare provider profile · identity verified
Rabee H Korbaj, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST PETERSBURG, FL · NPI 1932392073
Verified facts
What the public records show
CMS Open Payments records show Rabee H Korbaj, MD received $530.44 in general payments during 2025 across 23 reported records.
Coastal Medical Technologies LLC accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Coastal Medical Technologies LLC | Unresolved — no canonical attribution shown | $113.80 | 21.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.20 | 17.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.99 | 14.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.50 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.62 | 6.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.94 | 4.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.70 | 3.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.27 | 3.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.82 | 3.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.35 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.18 | 3.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.40 | 3.3% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $14.75 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.92 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $530.44 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.20 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.99 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.82 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 119 |
| Losartan Potassium | Losartan Potassium | 189 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 45 |
| Lisinopril | Lisinopril | 138 | 45 |
| Carvedilol | Carvedilol | 136 | 39 |
| Eliquis | Apixaban | 133 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 41 |
| Furosemide | Furosemide | 124 | 35 |
| Gabapentin | Gabapentin | 113 | 30 |
| Omeprazole | Omeprazole | 113 | 28 |
| Metformin Hcl | Metformin Hcl | 110 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 30 |
| Allopurinol | Allopurinol | 81 | 19 |
| Tramadol Hcl | Tramadol Hcl | 75 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 23 |
| Sertraline Hcl | Sertraline Hcl | 73 | 20 |
| Famotidine | Famotidine | 72 | 20 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Ozempic | Semaglutide | 66 | 13 |
| Nifedipine Er | Nifedipine | 64 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 26 |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Pregabalin | Pregabalin | 52 | 14 |
| Alprazolam | Alprazolam | 51 | 12 |
| Mounjaro | Tirzepatide | 50 | 12 |
| Spironolactone | Spironolactone | 50 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 25 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Finasteride | Finasteride | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 15 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 12 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Metronidazole | Metronidazole | 12 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Enbrel Mini | Etanercept | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Prednisone | Prednisone | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $530.44 · 23 records | Coastal Medical Technologies LLC | AIRSUPRA, APTIMA, AUSTEDO XR, CAPLYTA, COBENFY, Dexcom G6 Transmitter, FREESTYLE LIBRE 2, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Ozempic, QULIPTA, Rybelsus, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, UPTRAVI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error